March 3, 2025 10:46 AM ESTUpdated 04:00 PM
News Briefing

Genen­tech's TNKase gets new ap­proval; Sanofi gives up rights to on­col­o­gy can­di­date

ENDPOINTS

Plus, news about Nu­va­tion Bio, Leqem­bi, IN8bio and Sy­ros:

Long­time clot-bust­ing drug gets new ap­proval: Roche and Genen­tech’s TNKase (tenecteplase) was

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Af­ter Phase 3 de­pres­sion set­back, Neumo­ra paus­es two tri­als to make changes, scraps an­oth­er

Pro­tag­o­nist, Takeda's prof­it shar­ing deal un­der spot­light af­ter Phase 3 blood dis­or­der tri­al win

AD­Cs from a decade-old Sin­ga­pore biotech find new life with $187M

No­vo Nordisk signs $354M part­ner­ship with AI-guid­ed biotech for ‘risky’ new meta­bol­ic mech­a­nisms

Ab­b­Vie fi­nal­ly en­ters obe­si­ty race with $350M up­front for Gubra’s amylin

sponsored

The per­fect storm: Why every­thing is in place for 2025 to be the year of GxP AI

A service from the Financial Times